タリペキソール

タリペキソール 化学特性,用途語,生産方法

• 用途

  ドパミンD受容体アゴニストレボドパの長期使用による副作用を軽減する

• 効能

  パーキンソン病治療薬, ドパミンD2受容体作動薬

• 説明

  Domin was launched in Japan for Parkinson's disease. The compound is readily accessible in two steps from I-allylhexahydro-4H-azepin4-one. Its antiparkinson activity resides in the fact that talipexole is a selective agonist for presynaptic dopamine D₂ receptors with no D₁ receptor activity. It is a clonidine-like α₂-adrenoreptor agonist and has fewer GI side effects than bromocriptine the most widely used dopamine angonist. Also it is 70 times more potent than bromocriptine and has a more rapid onset of action. In addition to its anti-tremor activity there was a sedative effect but no emesis. The latter probably a result of talipexole's 5-HT₃ receptor antagonistic activity. Its metabolites have no biological activity, there was no development of tolerence and its effect could be enhanced by L-dopa.

• Originator

  Boehringer Ingelheim (Germany)

• brand name

  Domin

タリペキソール 上流と下流の製品情報

タリペキソール 生産企業

Global(38)Suppliers

101626-70-4, タリペキソール キーワード